A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment
Recruiting
18 years - 74 years
All
Phase
3
8 participants needed
1 Location
Brief description of study
Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment with Seltorexant
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Depression
-
Age: 18 years - 74 years
-
Gender: All
Male or female, aged 18 to 74 years (inclusive).
Is receiving and tolerating well any one of the
following SSRI or SNRI for depressive symptoms, in any formulation and
available in the participating country: citalopram, duloxetine, escitalopram,
fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline,
venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at
therapeutic dose level) for at least 6 weeks
Updated on
04 Aug 2024.
Study ID: 844597
Find a site
,
Your Information has been sent successfully.
Send a message
Enter your contact details to connect with study team
Primary Contact
